Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain

Launched by BEIJING HOSPITAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE · Apr 6, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach using a special type of warm plaster to help women who are dealing with the aftereffects of pelvic inflammatory disease and chronic pelvic pain. Chronic pelvic pain is a common issue that can cause ongoing discomfort in the lower abdomen and is often linked to infections that were not treated promptly. The trial aims to compare the effectiveness of this warm plaster with traditional treatments to see which one works better for relieving pain and improving overall health.

To participate, women aged 18 to 50 who have been diagnosed with pelvic inflammatory disease and are experiencing specific symptoms may be eligible. Participants will need to have a certain level of pain that is not too severe and must be willing to sign a consent form for treatment. The study is currently recruiting participants, and those who take part will receive either the new warm plaster treatment or the standard therapy, helping researchers learn more about the best ways to manage these conditions.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Meets the diagnostic criteria of traditional Chinese and Western medicine for sequelae of pelvic inflammatory disease and chronic pelvic pain;
• • 2. Transvaginal ultrasound examination shows thickening of the fallopian tube wall and fluid accumulation in the lumen, which may be accompanied by pelvic free fluid or fallopian tube ovarian masses;
• • 3. The age range is 18-50 years old, married or with a history of sexual activity;
• • 4. Those with a menstrual cycle of 21-35 days;
• • 5. 4 points ≤ Pain Visual Analog Scale (VAS) \< 7 points;
• • 6. Those who have signed an informed consent form and are willing to receive treatment.
• Exclusion Criteria:
• • 1. Female patients who have fertility requirements during pregnancy, lactation, or in the short term;
• • 2. Patients with gynecological diseases such as organic lesions of the reproductive system or gynecological acute abdomen;
• • 3. Chronic pelvic pain caused by gynecological tumors, endometriosis, pelvic congestion syndrome, uterine fibroids, tuberculous pelvic inflammatory disease, and other diseases confirmed through examination;
• • 4. Those with severe diseases such as cardiovascular, cerebrovascular, liver and kidney function, and digestive system;
• • 5. Individuals with mental abnormalities and psychological disorders;
• • 6. Individuals with allergic constitution or known allergies to the drugs and their components used in this experiment;
• • 7. Patients currently participating in clinical trials of other drugs;
• • 8. Other methods of treatment have already been or are currently being carried out, which may affect the indicators observed in this study.